Oculis (NASDAQ:OCS) Issues Earnings Results

Oculis (NASDAQ:OCS) released its quarterly earnings results on Tuesday. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.28), Zacks reports. Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%.

Oculis Stock Performance

Shares of NASDAQ:OCS traded down $0.19 on Thursday, hitting $18.66. 23,995 shares of the company were exchanged, compared to its average volume of 44,965. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average price is $20.86 and its 200 day moving average price is $16.88. Oculis has a 1-year low of $10.55 and a 1-year high of $23.08. The firm has a market capitalization of $755.60 million, a P/E ratio of -9.67 and a beta of 0.02.

Wall Street Analyst Weigh In

OCS has been the topic of a number of recent analyst reports. Chardan Capital reissued a “buy” rating and set a $28.00 price target on shares of Oculis in a report on Thursday. HC Wainwright cut their target price on Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Robert W. Baird lifted their target price on Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a research report on Thursday.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.